AI-assisted, human-published
03/26/2025 /Funding Events
Epicrispr Biotechnologies Secures $68 Million for FSHD Therapy Development
Epicrispr Biotechnologies raises significant funding to advance the development of EPI-321, a revolutionary therapy for FSHD, led by Ally Bridge Group and SOLVE FSHD.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com